Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. (Q39769344)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

main subject

phase III clinical trial

0 references

author

Patrick Phillips

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Andrew Nunn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Patrick P J Phillips

1

1 reference

14 September 2017

Andrew J Nunn

2

1 reference

14 September 2017

1 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

Future Medicinal Chemistry

26 January 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1273-1282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21426018%20AND%20SRC:MED&resulttype=core&format=json

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Whither short-course chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Global tuberculosis drug development pipeline: the need and the reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Survey of claims of no effect in abstracts of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Claims of equivalence in medical research: are they supported by the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

STREPTOMYCIN treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

The role of intention to treat in analysis of noninferiority studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Recurrent tuberculosis: relapse, reinfection, and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221

Impact of HIV Infection on the Recurrence of Tuberculosis in South India

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.221